ESCRS 2023: The three things that make this meeting a priority for Dr Sheng Lim

News
Video

The glaucoma specialist spoke about his ESCRS agenda–and his calendar for 2024

The annual European Society of Cataract and Refractive Surgeons (ESCRS) meeting is considered one of the most important events in ophthalmology. Our team spoke with Sheng Lim, MD, about glaucoma data he presented at the congress, what’s ahead in minimally invasive glaucoma surgery (MIGS) and why he makes the ESCRS meeting a priority each year.

Editor’s note: This transcript has been lightly edited for clarity.

Sheng Lim: My name is Sheng Lim, Professor of Glaucoma Studies at St. Thomas Hospital in King's College, London.

ESCRS is an important meeting for me. I'm always involved in the running of surgical courses, always present some data from my lab, always 1 or 2 papers, here, and presentations. It's also a very important meeting for the industry as well, because all the industries are here. So [it’s] become an important meeting for my calendar every year. So, 3 things: running courses, scientific presentations and meeting [the] industry.

[At ESCRS,] I'm going to have some new data that hasn't been published yet. I think it'll be quite interesting for people who are interested in MIGS devices. You'll be surprised to see some of these newer devices, how they work and how well they work. In a lot of them, these are the first studies that have been done in those devices.

I'm the chief investigator of a first randomised control trial on the [endoscopic cyclophotocoagulation] ECP laser in glaucoma. The data will be out, hopefully, in 2024. For me personally, that is the most exciting thing in my calendar. But, beyond that, there are 2 or 3 new glaucoma devices and surgical techniques that have only just been introduced, and I haven't tried those yet. So I'm looking forward to laying my hands on those, trying it out, and see how well it works. So [it's] quite exciting, here. I look forward to it.


Recent Videos
Thomas Aaberg, MD, gives an update on Neurotech Pharmaceuticals NT-501 device for the potential treatment of retinitis pigmentosa and age-related macular degeneration, including a projected PDUFA date from the FDA at the annual ASRS meeting in Stockholm, Sweden.
Sruthi Arepalli, MD, spoke with Modern Retina about her presentation, "Assessing retinal vascular changes in alzheimer disease with radiomics: A preliminary study of fundus photography" at the annual ASRS meeting in Stockholm, Sweden.
Nathan Steinle, MD, spoke with Modern Retina about the ongoing research on the durability of sozinibercept in combination therapy with anti-VEGF-A treatments at the annual ASRS meeting in Stockholm, Sweden.
Deepak Sambhara, MD, shared an overview of his paper-on-demand, which covered real-world safety and efficacy of aflibercept, 8 mg in the treatment of neovascular age-related macular degeneration at the annual ASRS meeting in Stockholm, Sweden.
Patrick C. Staropoli, MD, discusses clinical characterisation of Hexokinase 1 (HK1) mutations causing autosomal dominant pericentral retinitis pigmentosa
Richard B. Rosen, MD, discusses his ASRS presentation on illuminating subclinical sickle cell activities using dynamic OCT angiography
ASRS 2024: Socioeconomic barriers and visual outcomes in patients with rhegmatogenous retinal detachments, from Sally S. Ong, MD
Ashkan Abbey, MD, speaks about his presentation on the the CALM registry study, the 36-month outcomes of real world patients receiving fluocinolone acetonide 0.18 mg at the annual ASRS meeting in Stockholm, Sweden.
Nikoloz Labauri, MD, FVRS, speaks at the 2024 ASRS meeting about suspensory macular buckling as a novel technique for addressing myopic traction maculopathy
Jordana Fein, MD, MS, speaks with Modern Retina about the IOP outcomes with aflibercept 8 mg and 2 mg in patients with DME through week 48 of the phase 2/3 PHOTON trial at the annual ASRS meeting in Stockholm, Sweden.
© 2024 MJH Life Sciences

All rights reserved.